These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Magklara A; Scorilas A; Catalona WJ; Diamandis EP Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066 [TBL] [Abstract][Full Text] [Related]
3. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696 [TBL] [Abstract][Full Text] [Related]
4. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327 [TBL] [Abstract][Full Text] [Related]
5. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444 [TBL] [Abstract][Full Text] [Related]
6. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846 [TBL] [Abstract][Full Text] [Related]
7. The role of free prostate-specific antigen in the diagnosis of prostate cancer. Akdas A; Cevik I; Tarcan T; Turkeri L; Dalaman G; Emerk K Br J Urol; 1997 Jun; 79(6):920-3. PubMed ID: 9202560 [TBL] [Abstract][Full Text] [Related]
8. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA. Van Cangh PJ; De Nayer P; De Vischer L; Sauvage P; Tombal B; Lorge F; Wese FX; Opsomer R Urology; 1996 Dec; 48(6A Suppl):67-70. PubMed ID: 8973703 [TBL] [Abstract][Full Text] [Related]
9. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer. Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917 [TBL] [Abstract][Full Text] [Related]
11. The proportion of prostate-specific antigen (PSA) complexed to alpha(1)-antichymotrypsin improves the discrimination between prostate cancer and benign prostatic hyperplasia in men with a total PSA of 10 to 30 microg/L. Martínez M; España F; Royo M; Alapont JM; Navarro S; Estellés A; Aznar J; Vera CD; Jiménez-Cruz JF Clin Chem; 2002 Aug; 48(8):1251-6. PubMed ID: 12142381 [TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. Khosravi J; Diamandi A; Mistry J; Scorilas A J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033 [TBL] [Abstract][Full Text] [Related]
13. Free and total PSA in the diagnosis of prostate cancer. Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta AM Tumour Biol; 1997; 18(6):332-40. PubMed ID: 9372866 [TBL] [Abstract][Full Text] [Related]
14. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341 [TBL] [Abstract][Full Text] [Related]
15. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations. Veltri RW; Miller MC Urology; 1999 Apr; 53(4):736-45. PubMed ID: 10197849 [TBL] [Abstract][Full Text] [Related]
16. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; deKernion JB; Walsh PC; Scardino PT; Lange PH; Subong EN; Parson RE; Gasior GH; Loveland KG; Southwick PC JAMA; 1998 May; 279(19):1542-7. PubMed ID: 9605898 [TBL] [Abstract][Full Text] [Related]
17. Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions. Gion M; Mione R; Barioli P; Barichello M; Zattoni F; Prayer-Galetti T; Plebani M; Aimo G; Terrone C; Manferrari F; Madeddu G; Caberlotto L; Fandella A; Pianon C; Vianello L Clin Chem; 1998 Dec; 44(12):2462-70. PubMed ID: 9836713 [TBL] [Abstract][Full Text] [Related]
18. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer. Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767 [TBL] [Abstract][Full Text] [Related]
19. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer. Koliakos G; Chatzivasiliou D; Dimopoulos T; Trachana V; Paschalidou K; Galiamoutsas V; Triantos A; Chitas G; Dimopoulos A; Vlatsas G Dis Markers; 2000; 16(3-4):143-6. PubMed ID: 11381196 [TBL] [Abstract][Full Text] [Related]
20. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Björk T; Piironen T; Pettersson K; Lövgren T; Stenman UH; Oesterling JE; Abrahamsson PA; Lilja H Urology; 1996 Dec; 48(6):882-8. PubMed ID: 8973671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]